ClinicalTrials.gg
CompletedNCT07343999EFICAC-TTRUpdated Sep 25, 2026

EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac Amyloidosis

An interventional study of Home-Based Multicomponent Exercise Program and Microcrystalline Cellulose Control Supplementation in Transthyretin Cardiac Amyloidosis, sponsored by Universidad de Burgos. Completed at 3 sites in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Universidad de Burgos · Not applicable, Interventional, and Treatment

How we know

Updated Sep 25, 2026Now CompletedFirst site in Spain+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.

Enrollment
72nd of 96
47 · median 90
Started
2026
with 20 others
No phase
93 of 132
34 open now
Registered
108th of 132
by date
Lead sponsor
4 of 132
Universidad de Burgos

Among the 132 studies in Frailty with a site in Spain, this one is the 72nd largest by enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2026, is one of 93 with no phase, and was the 108th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Frailty with a site in Spain, or all of them as a file.
02

Study summary

Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.

EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.

A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.

The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.

Read the detailed description

Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.

In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.

Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.

03

Conditions studied

  • Transthyretin Cardiac Amyloidosis

Keywords

  • Exercise Training
  • Nutritional Supplementation
  • Creatine
  • Beta-Hydroxy Beta-Methylbutyrate
  • Older Adults
  • Functional Capacity
  • Frailty
  • Cardiac Amyloidosis
  • Transthyretin Cardiac Amyloidosis
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥70 years.
  • Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
  • Clinical stability during the 4 weeks prior to enrollment.
  • Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
  • Absolute medical to moderate-intensity exercise.
  • Severe comorbid conditions with an estimated \<6 months.
  • Severe cognitive impairment ( score \<20).
  • Concurrent participation in another clinical trial or structured exercise program.
  • Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
  • Severe renal impairment requiring dialysis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Other
    Usual Care

    Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.

    Other: Usual Care

  • Placebo comparator
    Exercise + Microcrystalline Cellulose Control Supplementation

    Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.

    Behavioral: Home-Based Multicomponent Exercise Program · Dietary Supplement: Microcrystalline Cellulose Control Supplementation

  • Experimental
    Exercise + Creatine and HMB Supplementation

    Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

    Behavioral: Home-Based Multicomponent Exercise Program · Dietary Supplement: Creatine and HMB Supplementation

Interventions

  • BehavioralHome-Based Multicomponent Exercise Program

    A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

  • Dietary supplementMicrocrystalline Cellulose Control Supplementation

    Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.

  • Dietary supplementCreatine and HMB Supplementation

    Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.

  • OtherUsual Care

    Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.

06

What researchers measure

Primary outcomes

  1. Change in Handgrip Strength

    Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  2. Change in 6-Minute Walk Test Distance

    Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Fat Mass

    Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  2. Change in Skeletal Muscle Mass

    Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  3. Change in Fat-Free Mass

    Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  4. Change in Phase Angle

    Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  5. Change in Frailty Status Assessed by the FRAIL Scale

    Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  6. Change in Short Physical Performance Battery (SPPB) Score

    Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  7. Change in Clinical Frailty Scale (CFS) Score

    Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.

    Time frame: Baseline and 12 weeks

  8. Change in Barthel Index Score

    Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.

    Time frame: Baseline and 12 weeks

  9. Change in SARC-F Score

    Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.

    Time frame: Baseline and 12 weeks

  10. Change in Minnesota Living With Heart Failure Questionnaire Score

    Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.

    Time frame: Baseline and 12 weeks

  11. Change in Charlson Comorbidity Index

    Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.

    Time frame: Baseline and 12 weeks

  12. Exercise Program Adherence

    Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.

    Time frame: Up to 12 weeks

  13. Supplement Adherence

    Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.

    Time frame: Up to 12 weeks

  14. Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score

    Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.

    Time frame: Baseline and 12 weeks

  15. Incidence of Intervention-Related Adverse Events

    Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.

    Time frame: Up to 12 weeks

  16. Rate of Supplement Discontinuation

    Proportion of participants who discontinue study supplementation during the intervention period.

    Time frame: Up to 12 weeks

  17. Change in Skeletal Muscle Index (SMI)

    Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

Other outcomes

  1. Change in Growth Differentiation Factor 15 (GDF-15)

    Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.

    Time frame: Baseline and 12 weeks

  2. Change in Soluble ST2

    Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.

    Time frame: Baseline and 12 weeks

  3. Change in Interleukin-6 (IL-6)

    Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.

    Time frame: Baseline and 12 weeks

  4. Change in C-Reactive Protein (CRP)

    Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.

    Time frame: Baseline and 12 weeks

  5. Change in circulating miR-21 expression

    Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  6. Change in circulating miR-29 expression

    Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  7. Change in circulating miR-34a expression

    Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  8. Change in circulating miR-155 expression

    Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  9. Change in PBMC Immune Polarization Profile by Flow Cytometry

    Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.

    Time frame: Baseline and 12 weeks

  10. Change in Pro-inflammatory (M1) Gene Expression Markers

    Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  11. Change in Anti-inflammatory (M2) Gene Expression Markers

    Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

    Time frame: Baseline and 12 weeks

  12. Change in Serum Albumin

    Change in serum albumin concentration (g/dL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  13. Change in Serum Prealbumin

    Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks

    Time frame: Baseline and 12 weeks

  14. Change in Vitamin D

    Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  15. Change in Galectin-3

    Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  16. Change in NT-proBNP

    Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  17. Change in High-Sensitivity Troponin T

    Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  18. Change in Leptin

    Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  19. Change in Adiponectin

    Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  20. Change in IGF-1

    Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

  21. Change in Klotho

    Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.

    Time frame: Baseline and 12 weeks

07

Study locations

3 sites
  • Hospital Santos Reyes
    Aranda de Duero, Castille and León, Spain
  • Hospital Universitario de Burgos
    Burgos, Castille and León 09006, Spain
  • Hospital Santa Bárbara
    Soria, Castille and León, Spain
08

References and documents

Publications

  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. No abstract available. PubMed 31081853 ↗
  • Ramos-Hernandez R, Miguel-Ortega A, Martinez-Ferran M, Fernandez-Lazaro D, Busto N, Mielgo-Ayuso J. Combined creatine and HMB co-supplementation improves functional strength independent of muscle mass in physically active older adults: a randomized crossover trial. Geroscience. 2026 Jun;48(3):4457-4475. doi: 10.1007/s11357-025-01889-y. Epub 2025 Oct 10. PubMed 41073834 ↗
  • de Souto Barreto P, Rolland Y, Vellas B, Maltais M. Association of Long-term Exercise Training With Risk of Falls, Fractures, Hospitalizations, and Mortality in Older Adults: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):394-405. doi: 10.1001/jamainternmed.2018.5406. PubMed 30592475 ↗
  • Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072. PubMed 33825853 ↗
  • Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. PubMed 31171094 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months after publication and ending 5 years after publication.

Access criteria: Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 7 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: start Jun 2026 → Feb 2026, primary completion Apr 2027 → Sep 2026 and completion Sep 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 15, 2026
StartActual
Feb 3, 2026was Jun 2026
Primary completionActual
Sep 10, 2026was Apr 2027
CompletionActual
Sep 10, 2026was Sep 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Sep 25, 2026
Sites
3 sites added — first site in Spain
Show 3 added (3 Spain)
  • Hospital Santos Reyes · Aranda de Duero, Spain
  • Hospital Universitario de Burgos · Burgos, Spain
  • Hospital Santa Bárbara · Soria, Spain
Sep 25, 2026
Start date
Jun 2026→Feb 3, 2026 (actual)
Sep 25, 2026
Primary completion
Apr 2027→Sep 10, 2026 (actual)
Sep 25, 2026
Study completion
Sep 2027→Sep 10, 2026 (actual)
Sep 25, 2026
Enrollment
102 (estimated)→47 (actual)
Sep 25, 2026
Interventions
Changed Fiber Supplementation (Microcrystalline Cellulose)→Microcrystalline Cellulose Control Supplementation. Arms added: Exercise + Microcrystalline Cellulose Control Supplementation; arms removed: Exercise + Fiber Supplementation (Active Control)
Sep 25, 2026
Secondary outcomes
1 edited, 2 time frame changed, 12 added, 4 removed, 6 description edited
What changed in the outcomes
  • AddedChange in Mini Nutritional Assessment Short-Form (MNA-SF) ScoreTime frame: Baseline and 12 weeks
  • AddedChange in Skeletal Muscle Index (SMI)Time frame: Baseline and 12 weeks
  • RemovedAll-Cause MortalityTime frame: Up to 6 months
  • RemovedIncidence of Heart Failure HospitalizationsTime frame: Up to 6 months
  • RemovedIncidence of Non-Heart Failure HospitalizationsTime frame: Up to 6 months
  • RemovedIncidence of Emergency Department VisitsTime frame: Up to 6 months
  • Time frameIncidence of Intervention-Related Adverse EventsUp to 6 months → Up to 12 weeks
  • Time frameRate of Supplement DiscontinuationUp to 6 months → Up to 12 weeks
  • DescriptionIncidence of Intervention-Related Adverse Events: how it is measured was reworded
  • DescriptionRate of Supplement Discontinuation: how it is measured was reworded
  • Editedother outcomeChange in PBMC MacrophageImmune Polarization (M1/M2)Profile by Flow CytometryTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in Serum AlbuminTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in Serum PrealbuminTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in Vitamin DTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in Galectin-3Time frame: Baseline and 12 weeks
  • Addedother outcomeChange in NT-proBNPTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in High-Sensitivity Troponin TTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in LeptinTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in AdiponectinTime frame: Baseline and 12 weeks
  • Addedother outcomeChange in IGF-1Time frame: Baseline and 12 weeks
  • Addedother outcomeChange in KlothoTime frame: Baseline and 12 weeks
  • Descriptionother outcomeChange in Anti-inflammatory (M2) Gene Expression Markers: how it is measured was reworded
  • Descriptionother outcomeChange in C-Reactive Protein (CRP): how it is measured was reworded
  • Descriptionother outcomeChange in Growth Differentiation Factor 15 (GDF-15): how it is measured was reworded
  • Descriptionother outcomeChange in Pro-inflammatory (M1) Gene Expression Markers: how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Completed
    3 sites added — first site in Spain
    Show 3 added (3 Spain)
    • Hospital Santos Reyes · Aranda de Duero, Spain
    • Hospital Universitario de Burgos · Burgos, Spain
    • Hospital Santa Bárbara · Soria, Spain
    Start date Jun 2026→Feb 3, 2026 (now actual)
    Primary completion Apr 2027→Sep 10, 2026 (now actual)
    Study completion Sep 2027→Sep 10, 2026 (now actual)
    Enrollment 102 (estimated)→47 (actual)
    Secondary outcomes 1 edited, 2 time frame changed, 12 added, 4 removed, 6 description edited
    What changed in the outcomes
    • AddedChange in Mini Nutritional Assessment Short-Form (MNA-SF) ScoreTime frame: Baseline and 12 weeks
    • AddedChange in Skeletal Muscle Index (SMI)Time frame: Baseline and 12 weeks
    • RemovedAll-Cause MortalityTime frame: Up to 6 months
    • RemovedIncidence of Heart Failure HospitalizationsTime frame: Up to 6 months
    • RemovedIncidence of Non-Heart Failure HospitalizationsTime frame: Up to 6 months
    • RemovedIncidence of Emergency Department VisitsTime frame: Up to 6 months
    • Time frameIncidence of Intervention-Related Adverse EventsUp to 6 months → Up to 12 weeks
    • Time frameRate of Supplement DiscontinuationUp to 6 months → Up to 12 weeks
    • DescriptionIncidence of Intervention-Related Adverse Events: how it is measured was reworded
    • DescriptionRate of Supplement Discontinuation: how it is measured was reworded
    • Editedother outcomeChange in PBMC MacrophageImmune Polarization (M1/M2)Profile by Flow CytometryTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in Serum AlbuminTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in Serum PrealbuminTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in Vitamin DTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in Galectin-3Time frame: Baseline and 12 weeks
    • Addedother outcomeChange in NT-proBNPTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in High-Sensitivity Troponin TTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in LeptinTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in AdiponectinTime frame: Baseline and 12 weeks
    • Addedother outcomeChange in IGF-1Time frame: Baseline and 12 weeks
    • Addedother outcomeChange in KlothoTime frame: Baseline and 12 weeks
    • Descriptionother outcomeChange in Anti-inflammatory (M2) Gene Expression Markers: how it is measured was reworded
    • Descriptionother outcomeChange in C-Reactive Protein (CRP): how it is measured was reworded
    • Descriptionother outcomeChange in Growth Differentiation Factor 15 (GDF-15): how it is measured was reworded
    • Descriptionother outcomeChange in Pro-inflammatory (M1) Gene Expression Markers: how it is measured was reworded
    Interventions Changed Fiber Supplementation (Microcrystalline Cellulose)→Microcrystalline Cellulose Control Supplementation. Arms added: Exercise + Microcrystalline Cellulose Control Supplementation; arms removed: Exercise + Fiber Supplementation (Active Control)
    + 7 other changes: index terms, verification date, oversight details, description, design details, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07343999
Lead sponsor
Universidad de Burgos
Collaborators
Hospital Universitario de Burgos
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Feb 3, 2026
Primary completion
Sep 10, 2026
Completion
Sep 10, 2026
Last update
Sep 25, 2026

Study contacts

Juan Mielgo-Ayuso, PhD
study director · Universidad de Burgos
José A Pérez Rivera, PhD, MD
principal investigator · Hospital Universitario de Burgos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion